Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | SNCA | P37840 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14682173 | 1.00 | ALDH1A1 (0.46) | ALDH1A1MAPTMEN1KMT2AAPP | |
| SCHEMBL11540789 | 1.00 | ALDH1A1 (0.46) | ALDH1A1MAPTMEN1KMT2AAPP | |
| SCHEMBL14341913 | 0.88 | MAPT (0.46) | ALDH1A1MAPTMEN1KMT2AAPP | |
| SCHEMBL20205919 | 0.85 | MAPT (0.46) | ALDH1A1MAPTMEN1KMT2AAPP | |
| SCHEMBL8027812 | 0.85 | KDM4E (0.43) | ALDH1A1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL24105689 | 0.82 | MAPT (0.42) | ALDH1A1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL13318788 | 0.80 | KDM4E (0.39) | ALDH1A1MAPTKDM4ENPC1RAB9A | |
| SCHEMBL13351584 | 0.80 | ALDH1A1 (0.39) | ALDH1A1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL11743822 | 0.80 | PIK3CA (0.43) | ALDH1A1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL11743813 | 0.80 | PIK3CA (0.43) | ALDH1A1MAPTMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220220102-A1 | D3 RECEPTOR AGONIST COMPOUNDS; METHODS OF PREPARATION; INTERMEDIATES THEREOF; AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2022-07-14 | — | — | US | disclosed |
| WO-2020228436-A1 | AROMATIC RING OR HETEROAROMATIC RING DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江海正药业股份有限公司 | 2020-11-19 | — | — | WO | disclosed |
| US-20190290645-A1 | Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2019-09-26 | — | — | US | disclosed |
| US-20190290645-A1 | Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2019-09-26 | — | — | US | disclosed |
| US-20170173009-A1 | Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. | 2017-06-22 | — | — | US | disclosed |
| US-20170173009-A1 | Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. | 2017-06-22 | — | — | US | disclosed |
| US-9586945-B2 | Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-03-07 | — | — | US | disclosed |
| US-9586945-B2 | Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-03-07 | — | — | US | disclosed |
| EP-2739614-B1 | AMINOCHROMANEs, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE DEUTSCHLAND (DE) | 2017-02-22 | — | — | EP | disclosed |
| EP-3057960-A1 | AMINOCHROMANE, AMINOTHIOCHROMANE AND AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-08-24 | — | — | EP | disclosed |
| US-20150111867-A1 | Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-04-23 | — | — | US | disclosed |
| WO-2015055770-A1 | AMINOCHROMANE, AMINOTHIOCHROMANE AND AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-04-23 | — | — | WO | disclosed |
| US-8853196-B2 | Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-10-07 | — | — | US | disclosed |
| EP-2739614-A1 | AMINOCHROMANE, AMINOTHIOCHROMANE AND AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co KG (DE) | 2014-06-11 | — | — | EP | disclosed |
| WO-2013020930-A1 | AMINOCHROMANE, AMINOTHIOCHROMANE AND AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO. KG (DE) | 2013-02-14 | — | — | WO | disclosed |
| US-20130035323-A1 | AMINOCHROMANE, AMINOTHIOCHROMANE AND AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO. KG (DE) | 2013-02-07 | — | — | US | disclosed |
| US-4169097-A | GASTRIC ANTISECRETORY AGENTS | MORTON-NORWICH PRODUCTS, INC. (US) | 1979-09-25 | — | — | US | disclosed |
| US-4115407-A | N-Benzyl-4-chromanamines | MORTON-NORWICH PRODUCTS, INC. (US) | 1978-09-19 | — | — | US | disclosed |
| US-4095023-A | 6-METHOXY-N-VANILLYLIDENE-4-CHROMANAMINE | MORTON-NORWICH PRODUCTS, INC. (US) | 1978-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220220102-A1 | D3 RECEPTOR AGONIST COMPOUNDS; METHODS OF PREPARATION; INTERMEDIATES THEREOF; AND METHODS OF USE THEREOF | DRD3, ADRB3, VDR | ALDH1A1 2173/4885MAPT 4182/4885MEN1 3664/4885 |
| US-20130035323-A1 | AMINOCHROMANE, AMINOTHIOCHROMANE AND AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | SLC7A1, BCAT1, AADAT | ALDH1A1 968/4885MAPT 861/4885MEN1 878/4885 |
| US-20150111867-A1 | Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy | SLC7A1, AADAT, BCAT1 | ALDH1A1 755/4885MAPT 998/4885MEN1 1088/4885 |
| US-20190290645-A1 | Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy | SLC7A1, BCAT1, AADAT | ALDH1A1 968/4885MAPT 861/4885MEN1 878/4885 |
| US-20170173009-A1 | Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy | SLC7A1, BCAT1, AADAT | ALDH1A1 694/4885MAPT 899/4885MEN1 1196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.